Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Blood Adv. 2017 Aug 17;1(19):1533-1536. doi: 10.1182/bloodadvances.2017007526. eCollection 2017 Aug 22.

Authors

Larisa Broglie^{1

2}, Lauren Pommert^{2

3}, Sridhar Rao⁴, Monica Thakar^{1

2}, Rachel Phelan^{1

2}, David Margolis^{1

2}, Julie Talano^{1

2}

Affiliations

¹ Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
² Children's Hospital of Wisconsin, Milwaukee, WI.
³ Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI; and.
⁴ Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI.

Abstract

Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Grants and funding